I am a
Home I AM A Search Login

Papers of the Week


2021 Jan 29


Diabetes Obes Metab

Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial.

Authors

He YL, Pachori A, Chen P, Ma S, Mendonza AE, Amer A, Marbury TC, Hinder M
Diabetes Obes Metab. 2021 Jan 29.
PMID: 33512754.

Abstract

The beneficial effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) have been demonstrated. Whether inhibition of both SGLT1 and SGLT2 confers additional benefits is unknown. This study investigated the glucosuric, renal and hemodynamic effects of a dual SGLT1/2 inhibitor, licogliflozin, in patients with CKD.